Phase 2TerminatedAge-related condition
Extension Study of Participants From SPG302-ALS-001
An Open-label Extension of SPG302-ALS-001 Study to Evaluate the Long-term Safety and Efficacy of Daily Oral SPG302 Treatment in Participants With Amyotrophic Lateral Sclerosis
- Sponsor
- Spinogenix (Industry)
- Enrolment
- 16 enrolled
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- SPG302
- Ages
- adults, older adults
- Registry
- NCT06903286
Full record on ClinicalTrials.gov
From the registry
This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALS-101 with Amyotrophic Lateral Sclerosis (ALS)
Primary outcomes
- Treatment emergent adverse events and serious adverse events
- C-SSRS (Columbia Suicide Severity Rating Scale)
History
Last registry update
Study completion
Primary completion
Started
Registered